SecBot SecBot
PRESS-RELEASE ·Filed Jun 22, 2026

PVLA

Palvella Therapeutics Inc.
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Rolling review accelerates the NDA review process, reducing time-to-potential approval. Traders should watch for completion of the NDA submission in H2 2026 and any FDA communication on acceptance or priority review. The stock may re-rate on regulatory progress milestones.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$118.84
T+0 close · Jun 22, 2026 · via day close
Latest settled
+27.25%
T+60 · $151.22
Vs SPY
+25.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $118.84entry
  2. T+1 · 5mo ago −0.13%α +1.32% · $118.68
  3. T+5 · 5mo ago +24.71%α +26.78% · $148.21
  4. T+20 · 4mo ago +32.31%α +32.46% · $157.24
  5. T+60 · 2mo ago +27.25%α +25.50% · $151.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics announced that the FDA has granted rolling review for its NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations. The company remains on track to complete the NDA submission in the second half of 2026. This regulatory milestone accelerates the review timeline for a potential first-approved therapy in an indication with no current FDA-approved treatments, a significant catalyst for this clinical-stage biotech.

Key Facts

  • FDA granted rolling review for QTORIN™ rapamycin NDA for microcystic lymphatic malformations.
  • Palvella remains on track to complete NDA submission in the second half of 2026.
  • QTORIN™ rapamycin has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA.
  • No FDA-approved therapies currently exist for the estimated 30,000+ U.S. patients with microcystic LMs.
  • Positive Phase 3 SELVA results support the NDA submission.

Financial Impact

First-to-market potential in a rare disease with 30,000+ U.S. patients; no revenue or deal value disclosed.

pipeline valueregulatory timelinemarket opportunity

Risk Factors

  • FDA may still issue a Complete Response Letter (CRL) after review, including on safety/efficacy or CMC grounds.
  • Commercial adoption depends on pricing, reimbursement, and competition from off-label systemic mTOR inhibitors.
  • Company is clinical-stage with no approved products and may require additional capital to fund commercialization.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3315197

US Market Status

Market Closed · Opens in 6h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026